ADOC Adocia SA

3.669USD3.338 EUR · EPA-5.12%Mkt Cap: 81.97M USDP/E: —

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. The company's proprietary BioChaperone technological platform provides molecular delivery of ther…

Key Statistics

Company
Market Cap81.97M USD
Enterprise Value70.97M USD
Revenue (TTM)3.28M USD
Gross Profit750.75K USD
Net Income (TTM)-18.24M USD
Revenue/Share0.17 USD
Last Price3.669 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees80
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0011184241
Valuation
P/E (Trailing)—
P/E (Forward)-0.46
PEG—
EV/EBITDA-4.53
EV/Revenue21.65
P/S25.01
P/B-14.38
EPS (TTM)-0.93 USD
EPS (Forward)-7.86 USD
52W Range
2.22020% of range9.464
52W High9.464 USD
52W Low2.220 USD
Profitability
Gross Margin46.31%
Oper. Margin-495.54%
EBITDA Margin0.00%
Profit Margin-1124.81%
ROE-1112.74%
ROA-58.31%
ROIC—
ROCE-186.94%
Growth
Revenue Growth-39.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.18M USD
CapEx (TTM)293.49K USD
FCF Margin-1.43%
FCF Yield-0.06%
Net Debt-1.47M USD
Net Debt/EBITDA0.09
Net Debt/FCF—
Balance Sheet
Debt/Equity5.97
Current Ratio0.88
Quick Ratio0.83
Book Value/Sh-0.25 USD
Cash/Share0.54 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.39 USD
Upside (mean)+183.1%
Target Range5.276 USD – 13.19 USD
5.276+183.1% to mean13.19
# Analysts4
Ownership
Shares Out.22.64M
Float16.99M
Insiders8.81%
Institutions7.00%
Technical
SMA 503.267 (+12.3%)
SMA 2004.728 (-22.4%)
Beta0.35
S&P 52W Chg8.68%
Avg Vol (30d)551.31K
Avg Vol (10d)912.12K
Technical Indicators
RSI (14)50.2
MACD0.2664
MACD Signal0.2760
MACD Hist.-0.0096
BB Upper5.120 USD
BB Middle3.714 USD
BB Lower2.308 USD
BB Width75.72%
ATR (14)0.4223 USD
Vol Ratio (20d)0.44x

About Adocia (EPA: ADOC)

›

Adocia (EPA: ADOC) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 80 employees.

The shares were at 3.338 EUR on 20 November 2026, down 59.5% over 52 weeks. Its 52-week range is 2.020 EUR to 8.610 EUR: the price is 61.2% below the high and 65.2% above the low.

Its market capitalisation is 74.57M EUR.

Adocia reports an operating margin of -495.5% and revenue down 39.4% year over year.

It holds more cash than debt, a net cash position of 1.34M EUR. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 9.450 EUR is 183.1% above the current price.